A recent prospective imaging study determined that the overall prevalence of older adults with cerebral cavernous malformation (CCM) is 0.46%. The findings and data from this study are important for determining the potential number of patients available for cohort studies and anticipated clinical trials in patients with CCM. Researchers included 4,721 participants aged 50 to 89 years who were enrolled between January 1, 2004, and December 15, 2015, in the Mayo Clinic Study of Aging, a longitudinal, population-based study. Participants were invited to undergo brain magnetic resonance imaging (MRI). Of total participants, 2,715 had an evaluable MRI. They found:
- Of total participants who underwent MRI scans, 12 (0.44%) had CCM.
- With the use of inverse probability weights to adjust for participation bias, the overall prevalence was 0.46%.
- The age-adjusted prevalence was found to be 0.61% for the 50- to 59-year age group, 0.17% for the 60- to 69-year age group, 0.45% for the 70- to 79-year age group, and 0.58% for the 80- to 89-year age group.
- The sex-adjusted prevalence was 0.41% for women and 0.51% for men.
Flemming KD, Graff-Radford J, Aakre J, et al. Population-based prevalence of cerebral cavernous malformations in older adults. Mayo Clinic Study of Aging. [Published online ahead of print May 8, 2017]. JAMA Neurol. doi:10.1001/jamaneurol.2017.0439.
This Week's Must Reads
Risk Factors for Suicidality in Huntington Disease, Neurology; ePub 2019 Mar 8; McGarry, et al
Socioeconomic Disparities in US Stroke Survivors, Stroke; ePub 2019 Mar 11; Elfassy, Grasset, et al
Treating Stroke Patients with tPA via Telemedicine, Stroke; ePub 2019 Mar 11; Wysocki, et al
Can a Modified Ketogenic Diet Reduce Seizures?, Epilepsy Behav; ePub 2019 Mar 10; Roehl, et al
No Association Between Self-Reported TBI and AD, Alzheimers Dement; ePub 2019 Mar 6; Sugarman, et al
Must Reads in Rare Diseases
FDA Approves Firdapse for Rare Autoimmune Disorder, FDA news release; 2018 Nov 28
Treatment Outcomes Post-Surgery for Moyamoya Disease, J Neurol; ePub 2018 Sep 8; Kahn, Kaur, Stein, et al
FDA Approves Drug for Rare Peripheral Nerve Disease, FDA Web site; 2018 Aug 10
FDA Approves Hizentra for CIDP Treatment, CSL Behring news release; 2018 Mar 16
Cerebral Cavernous Malformation in the Elderly , JAMA Neurol; ePub 2017 May 8; Flemming, et al